SLU-PP-332 + Retatrutide Stack: Eat Less, Burn More

SLU-PP-332 and retatrutide are the two compounds most often paired in community body-recomposition protocols built around the largest-effect-size weight-loss mechanism plus an exercise-mimetic floor. Mechanistically the case is clean: retatrutide reduces caloric intake and modestly increases expenditure through GLP-1, GIP, and glucagon agonism. SLU-PP-332 increases skeletal muscle oxidative capacity and mitochondrial output through ERR pan-agonism. The pathways do not overlap.

Research-context information only. SLU-PP-332 and retatrutide are both investigational drugs not approved by the FDA. SLU-PP-332 has only mouse data; retatrutide has Phase 2 and Phase 3 trial data but is not yet FDA-approved. The combination has not been tested in any published clinical trial. Protocols, doses, and reactions reported below come from per-compound literature and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

What the case lacks: any published trial of the combination. Retatrutide has Phase 2 (Jastreboff et al., NEJM 2023, PMID 37366315) and Phase 3 (TRIUMPH-4, Bays et al., NEJM 2025, PMID 41090431) data. SLU-PP-332 has only mouse data. The stack lives entirely in community-protocol territory.

This guide walks through the mechanistic case, the per-compound dose framework, the sequencing community references describe, and the open questions a careful researcher would flag.

Mechanism: Why the Pairing Is Mechanistically Clean

The "cleanest stack on paper" framing comes from the fact that the four signaling pathways involved are non-overlapping at the receptor level.

Retatrutide's three pathways converge on satiety-driven caloric deficit plus a metabolic-rate increase. SLU-PP-332's pan-ERR pathway converges on mitochondrial mass and oxidative capacity. The first set is dominated by central nervous-system signaling (hypothalamus, NTS, area postrema). The second is dominated by peripheral skeletal muscle and adipose tissue.

The plausible additivity: retatrutide provides the deficit; SLU-PP-332 makes the deficit easier to sustain by improving substrate oxidation in the tissues being asked to burn fat. This is the body-recomposition framing — a deficit run on improved oxidative machinery.

The plausible failure mode: ERR pan-agonism does not change appetite. If retatrutide is already producing maximum tolerable appetite suppression, adding SLU-PP-332 may not move the rate of weight loss meaningfully. The fat-loss numbers in mice on SLU-PP-332 monotherapy were dramatic (~12% in 28 days) but were measured against a high-fat diet without GLP-1 agonism on board.

Per-Compound Dose Framework

Neither compound has been studied at maintenance combination doses. The framework below is the per-compound community baseline; the stack does not change either compound's titration cadence.

Retatrutide (community-reported titration)

The Jastreboff 2023 Phase 2 trial used a structured ramp to 12 mg/week. Community-reported retatrutide protocols deliberately stay below trial peak because of GI tolerability:

For the standalone retatrutide dosing detail, see the Retatrutide Dosing Guide.

SLU-PP-332 (community-reported, route-dependent)

Mouse studies dosed 25 mg/kg IP twice daily — not directly translatable to humans. Community injectable protocols cluster well below the allometric-scaled equivalent. Oral capsule formats may produce no systemic exposure (Billon 2025, PMID 41421047, identifies the parent compound's lack of oral bioavailability as the motivation for SLU-PP-915).

For the full SLU-PP-332 dosing breakdown, see the SLU-PP-332 Dosing Guide.

Sequencing — What Community References Describe

The most-described community sequencing pattern:

1. Months 0–3: Retatrutide titration alone, ramping toward 2 mg/week maintenance. Stabilize tolerance, characterize personal GI response, establish baseline weight-loss trajectory.
2. Months 3+: Once retatrutide is stable at 2 mg/week (or the user's chosen maintenance), layer SLU-PP-332 at low community doses on a fresh titration of its own.
3. Throughout: Adjust retatrutide upward only if the body-composition trajectory has plateaued and tolerability is acceptable; SLU-PP-332 dose changes are independent of the retatrutide schedule.

The reasoning: the GLP-1/GIP/glucagon axis dominates the acute side-effect profile. Stabilizing it first means any new effect after adding SLU-PP-332 is more interpretable. This is the same logic that drives the retatrutide + cagrilintide stacking sequencing, and applies for the same reason.

What the Stack Is Actually Asked to Do

Three different framings drive different community use cases.

Frame 1 — Plateau-breaking on retatrutide monotherapy

Some community users report weight-loss plateaus 6–12 months into a retatrutide protocol. The hypothesis: adding a non-overlapping output pathway (mitochondrial biogenesis + fatty acid oxidation via ERR) extends weight loss past the plateau without further increasing the GI burden of upping retatrutide's dose.

What the data say: unstudied. Community reports are split — some describe modest renewed weight loss, others describe no change. The same caveat that applies to all SLU-PP-332 reports applies here: oral cap users may be reporting placebo, and even injectable users are below mouse-scaled doses.

Frame 2 — Body recomposition during the cut

Retatrutide's glucagon-receptor activation supports lean-mass preservation better than pure GLP-1 agonists, but lean-mass loss during aggressive deficits is a known issue across the class. The hypothesis: SLU-PP-332's type IIa oxidative fiber shift maintains muscle quality during the deficit, even if it does not directly drive hypertrophy.

What the data say: the Billon 2023 exercise-capacity paper documented a fiber-type shift toward type IIa oxidative fibers in mice — that is the relevant data point. Whether the same fiber-type shift maintains lean mass during a human caloric deficit is unstudied.

Frame 3 — Maintenance with metabolic floor

After the cut, some community users frame SLU-PP-332 as a "metabolic floor" they hold while titrating retatrutide down. The logic: ERR pan-agonism keeps mitochondrial output elevated even as the GLP-1 deficit signal wanes during retatrutide tapering.

What the data say: unstudied. Both compounds in this maintenance use case lack data.

What's Different vs Retatrutide + Cagrilintide

The two stacks built around retatrutide are SLU-PP-332 + retatrutide and cagrilintide + retatrutide. They solve different problems.

The cagrilintide stack adds another intake-reduction pathway. The SLU-PP-332 stack adds an output-increase pathway. They are not interchangeable, and stacking all three is rarely described in conservative community protocols.

Practical Combination Considerations

Injection sites and timing. Retatrutide is injected once weekly (or split 2-3×/week) subcutaneously. SLU-PP-332 injectable is daily or BID. Community references describe rotating sites and avoiding same-site stacking on the same day.

Reconstitution and storage. Both compounds use bacteriostatic water reconstitution. SLU-PP-332 may benefit from a small DMSO co-solvent due to lipophilicity. Both reconstituted vials are refrigerated 2–8 °C; SLU-PP-332 reconstituted vials are stable ~28 days, retatrutide reconstituted vials are stable 4 weeks at 2–8 °C per common community protocols.

Cycling. Retatrutide is run continuously in trial protocols. SLU-PP-332 community use cycles 4–8 weeks on / off — meaning the stack typically has SLU-PP-332 cycled around a continuous retatrutide base.

Monitoring. A standard pre-cycle metabolic panel covers both compounds. Adding lactate as a SLU-PP-332-specific functional biomarker is community-described — see the SLU-PP-332 Bloodwork & Biomarkers guide.

Open Questions a Careful Researcher Would Flag

• Does SLU-PP-332 produce a measurable additional rate of weight loss on top of retatrutide at community doses, or does it just contribute subjective endurance changes?
• Does the type IIa fiber shift translate to better-preserved lean mass during a sustained retatrutide-driven deficit?
• Does the cardiac safety signal in the Xu 2023 paper (improved EF in mouse heart failure, no pathological hypertrophy) hold up in healthy human cardiac tissue under chronic exposure alongside a triple-agonist?
• Does ERR pan-agonism interact pharmacokinetically with retatrutide's clearance pathway? Untested.
• What is the right reverse-titration order — drop SLU-PP-332 first, retatrutide first, or both together?

None of these questions has published data behind it.